Matt CohenPartner at Osage University Partners
Matt joined OUP in 2013 and focuses on investments in therapeutics, diagnostics, medical devices, and research tools. He has been involved with OUP’s investment in several portfolio companies including Kura Oncology (NASDAQ: KURA), Cell Design Labs (acquired by Gilead), Biohaven Pharma (NYSE: BHVN), Arrakis Therapeutics, PMV Pharma, and others. Prior to joining OUP, Matt was a strategy consultant with L.E.K. Consulting serving clients in biopharma, diagnostics, research tools, healthcare, and private equity.
Matt holds a Ph.D. in Cell and Molecular Biology from The University of Pennsylvania, and a B.S. in Microbiology from The Pennsylvania State University.